Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
19 December 2022Website:
http://www.lipella.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | 2 min agoDividend
Analysts recommendations
Institutional Ownership
LIPO Latest News
PITTSBURGH, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (the “Company,” “our” or “us”), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. Eastern Time on November 7, 2024 upon the filing of a certificate of amendment to the Company's certificate of incorporation with the Secretary of State of the State of Delaware.
PITTSBURGH, PA, November 1, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc.
PITTSBURGH, Pa., Oct. 29, 2024 – PRISM MediaWire – Lipella Pharmaceuticals, Inc.
PITTSBURGH, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman, PhD will be presenting at the 2024 Spartan Capital Investor Conference that is being held on November 4, 2024, at the Pierre Hotel in New York. Event: Lipella Presentation - 2024 Spartan Capital Investor Conference Date: Monday, November 4th, 2024 Time: 9:25 am EST Jonathan Kaufman will be available for one-on-one meetings with registered investors of the conference.
PITTSBURGH, PA, October 15, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company focused on developing therapies for serious diseases with unmet medical needs, today announced the receipt of a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for its proprietary liposomal drug delivery platform.
Patent application covers key technology innovations for delivering therapeutic agents Proprietary technology enables precise delivery to improve safety and efficacy in oncology, cancer survivorship and immunotherapy Allowance provides broad IP protection for drug-delivery platform and extends market exclusivity for two lead clinical assets currently in Phase 2 trials PITTSBURGH, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company focused on developing therapies for serious diseases with unmet medical needs, today announced the receipt of a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for its proprietary liposomal drug delivery platform. The patent application, U.S. Patent No.
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive Q&A with Dr. Michael Chancellor, Co-founder and Chief Medical Officer of Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO).
PITTSBURGH, Sept. 24, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced an update on its ongoing multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus (OLP).
Pittsburgh, PA, August 22, 2024 – Lipella Pharmaceuticals, Inc. (NASDAQ: LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry. This online platform is designed to enhance research and drive the development of new treatments for OLP, a chronic inflammatory disease affecting the mucous membranes of the mouth.
Pittsburgh, PA, August 21, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotech company, will highlight clinical data on LP-20, a novel MRI contrast agent designed for diagnosing interstitial cystitis and detecting bladder cancer at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto, Japan, taking place August 21-23, 2024.
- 1(current)
What type of business is Lipella Pharmaceuticals Common Stock?
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
What sector is Lipella Pharmaceuticals Common Stock in?
Lipella Pharmaceuticals Common Stock is in the Healthcare sector
What industry is Lipella Pharmaceuticals Common Stock in?
Lipella Pharmaceuticals Common Stock is in the Biotechnology industry
What country is Lipella Pharmaceuticals Common Stock from?
Lipella Pharmaceuticals Common Stock is headquartered in United States
When did Lipella Pharmaceuticals Common Stock go public?
Lipella Pharmaceuticals Common Stock initial public offering (IPO) was on 19 December 2022
What is Lipella Pharmaceuticals Common Stock website?
https://www.lipella.com
Is Lipella Pharmaceuticals Common Stock in the S&P 500?
No, Lipella Pharmaceuticals Common Stock is not included in the S&P 500 index
Is Lipella Pharmaceuticals Common Stock in the NASDAQ 100?
No, Lipella Pharmaceuticals Common Stock is not included in the NASDAQ 100 index
Is Lipella Pharmaceuticals Common Stock in the Dow Jones?
No, Lipella Pharmaceuticals Common Stock is not included in the Dow Jones index
When was Lipella Pharmaceuticals Common Stock the previous earnings report?
No data
When does Lipella Pharmaceuticals Common Stock earnings report?
Next earnings report date is not announced yet